The 20 Best Metastatic Brain Tumor Doctors Near Me in Rosedale, MD

Russell Hales, M.D., is an assistant professor of radiation oncology and molecular radiation sciences at the Johns Hopkins University School of Medicine. He also is director of the thoracic multidisciplinary clinic. His research focuses on reconstructing health delivery models to enhance value and improve clinical outcomes. He also studies the effect of immunotherapy and RT in thoracic tumors. Dr. Hales was awarded an R21 grant to study the use of dynamic MRI in predicting tumor motion in patient with lung cancer. Taken together, his research focuses on optimizing patient outcomes using resources from physics, engineering, biology and health delivery systems. Dr. Hales’ efforts extend beyond radiation oncology and clinical management. He has helped to lead in the thoracic oncology program, which includes 20 faculty members and nearly 50 staff, to help chart a vision for this program’s future. In the last four years, the program has gradually transitioned from The Johns Hopkins Hospital campus to Johns Hopkins Bayview Medical Center. Dr. Hales was tasked to head the building and design committee that worked with architects to create a structure conducive to 21st century oncology care. His work extends beyond the bricks and mortar of the new cancer center today to team development within the thoracic oncology program. Simply put, the thoracic oncology move was designed to conceptualize the transition of care from department-based to disease-based medicine. As such, Dr. Hales has worked to integrate the efforts of specialists in medical oncology, thoracic surgery, interventional pulmonology, pathology and radiology. These experts share a clinical space focused on thoracic malignancies and bring a patient-centered model of care to their group. Dr. Hales graduated from Brigham Young University Summa Cum Laude and Valedictorian in 2001. He attended Johns Hopkins Medicine and graduated with an M.D. in 2005. He trained on the Osler Medical Service and attended residency at Johns Hopkins. He joined the faculty at Hopkins in 2010. Dr. Hales focus in program building, research and clinical endeavors is robust, but he understands the key role of academia in training future leaders in medicine. He has been awarded Teacher of the Year in the department of radiation oncology at Hopkins for three of the last six years. He is a well-respected lecturer and travels nationally to speak at conferences and educational workshops about novel therapies in lung and esophagus cancer. Make A Gift. Dr. Hales is rated as an Advanced provider by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Thymic Epithelial Tumor, Non-Small Cell Lung Cancer (NSCLC), and Endoscopy. Dr. Hales is board certified in American Board Of Radiology.

Dr. Debraj “Raj” Mukherjee’s clinical focus is the treatment of patients with primary and metastatic brain lesions. His clinical work and research emphasize the development of individual treatment plans that optimize survival and quality of life in all patients. After receiving his medical degree from Dartmouth Medical School, Dr. Mukherjee was recruited to Johns Hopkins, where he studied epidemiology, biostatistics and clinical design at the Johns Hopkins Bloomberg School of Public Health and served as Director of the Neuro-Oncology Surgical Outcomes Laboratory in the Department of Neurosurgery. Dr. Mukherjee completed neurosurgery residency at Cedars-Sinai Medical Center, where he was named a Robert Wood Johnson Foundation Health & Society Scholar. He completed an open and endoscopic skull base fellowship with the Center for Skull Base Surgery at University of Pittsburgh Medical Center, where he was a Copeland Scholar. Throughout his career, Dr. Mukherjee has led patient-centered research pursuits in neuro-oncology including development of a national registry for patients with brain tumors, creation of disease-specific quality of life instruments for patients with skull base tumors, and development of innovative clinical trials in neuro-oncology. He leads the Meningioma, Brain Metastasis, and Neurosurgical Oncology centers at Johns Hopkins Medicine, and he serves as Assistant Residency Program Director for one of the largest neurosurgical training programs in the country. His work has been supported by the American Medical Association, Glioblastoma Foundation, National Institute on Aging, and National Cancer Institute. Dr. Mukherjee can be contacted at drraj@jhmi.edu. Dr. Mukherjee is rated as an Advanced provider by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 31 other conditions, according to our data. His clinical expertise encompasses Meningioma, Pituitary Tumor, Brain Tumor, Awake Craniotomy, and Craniectomy. Dr. Mukherjee is board certified in American Board Of Neurological Surgery.

Dr. Kleinberg specializes in the radiation treatments, including stereotactic radiosurgery, of brain and spinal tumors. Areas of research include both tumors arising in the central nervous system and tumors metastasizing from other locations. He also specializes in the treatment of esophageal tumors and has led national clinical trials in both therapy of brain tumors as well as esophageal cancer. Dr. Kleinberg has been recently named in the US News and World Report list of top 1% of doctors in his specialty. He is the co-chair of the Eastern Cooperative Oncology Group Brain Tumor Working Group, Vice-Chair of the NCI Cooperative Group Steering Committee for Esophageal and Gastric Tumors, and is a member of the NCI Cooperative Group Steering Committee for Gastrointestinal Tumors. He is also on the American College of Radiation Oncology Neurologic Cancer Practice Accreditation Team. Make A Gift. Dr. Kleinberg is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Brain Tumor, Hepato-Pancreato-Biliary Surgery, and Gamma Knife Radiosurgery. Dr. Kleinberg is board certified in American Board Of Radiology.

Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Glioma, Glioblastoma, Astrocytoma, and Brain Tumor. Dr. Holdhoff is board certified in American Board Of Internal Medicine.

Dr. Jon Weingart focuses on the surgical treatment of brain tumors including benign and malignant tumors. Dr. Weingart also specializes in spinal disorders, such as cervical and lumbar disc disease, as well as other congenital and developmental abnormalities such as tethered spinal cord, spina bifida and chiari malformation. Dr. Weingart is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 36 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, Awake Craniotomy, and Osteotomy. Dr. Weingart is board certified in American Board Of Neurological Surgery.

Dr. Kristin Redmond specializes in the treatment of brain tumors and leads the spinal radiosurgery program. She received her undergraduate degree from Princeton University where she graduated magna cum laude with a focus in neuro-psychology. She attended medical school and obtained a Masters in Public Health in health systems management at Tulane University where she was elected to the Alpha Omega Alpha Honor Medical Society as well as the Gold Humanism in Medicine Honor Society. Dr. Redmonds research interest focuses on the development of novel radiation techniques and therapeutic agents to treat brain and spine tumors in order to increase tumor control and overall survival. In addition, she is working to develop innovative approaches to try to limit long term toxicities and minimize neuro-cognitive dysfunction following treatment for tumors of the central nervous system. Dr. Redmond believes in a holistic approach to medicine and feels that the social and psychological components of patient care are equally important to traditional therapies. She works closely with a team of specialists to support patients and families during their cancer journey. Make A Gift. Dr. Redmond is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. She is also highly rated in 33 other conditions, according to our data. Her clinical expertise encompasses Chordoma, Brain Tumor, Astrocytoma, and Metastatic Brain Tumor. Dr. Redmond is board certified in American Board Of Radiology.

David Kamson is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Kamson is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioblastoma, Metastatic Brain Tumor, Gliosarcoma, and Hormone Replacement Therapy (HRT). Dr. Kamson is board certified in American Board Of Psychiatry And Neurology.

Karisa Schreck is co-director of the BRAF Brain Tumor Center at Johns Hopkins. Her research focuses on the development of small-molecule targeted therapies for patients with primary brain tumors. Dr. Schreck has specific expertise in the treatment of BRAF gene mutations. As such, she works with Christine Pratilas’ laboratory to investigate resistance mechanisms to BRAF-targeted therapy. Dr. Schreck also writes and runs clinical trials for novel targeted agents through the Comprehensive Brain Tumor Center and the Alliance for Clinical Trials in Oncology. Dr. Schreck is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Glioma, Brain Tumor, Astrocytoma, and Glioblastoma. Dr. Schreck is board certified in American Board Of Psychiatry And Neurology.

Stephen Ronson is a Radiation Oncologist practicing medicine in Rosedale, Maryland. Dr. Ronson is rated as an Advanced provider by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Primitive Neuroectodermal Tumor (PNET), and Posterior Fossa Tumor.

Kelly Orwat is a Radiologist practicing medicine in Rosedale, Maryland. Dr. Orwat is rated as an Advanced provider by MediFind in the treatment of Metastatic Brain Tumor. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Metastatic Brain Tumor, and Primitive Neuroectodermal Tumor (PNET).

Dr. Lam treats patients with lung cancer, esophageal cancer, mesothelioma, and other thoracic cancers. He directs the Thoracic Oncology Clinical Research Program and the Esophageal Cancer Research Program at Johns Hopkins. Dr. Lam is a clinical and translational researcher with a focus on cancer genomics, liquid biopsies, and novel immunotherapies such as vaccines and cell therapies. He has been recognized with a Conquer Cancer Foundation/ASCO Career Development Award, an LCFA/IASLC/BMS Young Investigator Award, and as a Gilead Research Scholar. Dr. Lam is rated as an Experienced provider by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Hepatectomy, and Hepato-Pancreato-Biliary Surgery.

Dr. K. Ranh Voong specializes in thoracic malignancies, including lung, esophageal, thymic cancers, and mesothelioma. She treats patients at both the Johns Hopkins Thoracic Center of Excellence at Johns Hopkins Bayview and at the Proton Center at Sibley Memorial Hospital. She has extensive expertise in proton therapy, SBRT, IMRT for tumors involving the chest. She is the Principal Investigator on grants from Lung Cancer Research Foundation and Hopkins-Wellspan. She is the Principal Investigator of a prospective study evaluating the immunogenic effects of SABR alone on systemic T cell response in patients with stage I NSCLC. She is the principal investigator of a multi-institutional prospective trial showing that routine review of patient-reported outcome measures informs radiation on-treatment toxicity burden assessment and care delivery. She was the Quality of Life Co-chair of a Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma (NRG-LU006). She has been invited to participate in national and regularly lectures on thoracic malignancies and protons for thoracic malignancies therapy. In her research, Dr. Voong is dedicated to improving the outcomes of patients with thoracic malignancies, by exploring avenues to better understand and optimize the delivery of radiotherapy. Dr. Voong is also the Program Director for the Radiation Oncology Residency Program. She mentors residents, medical students. Make A Gift. Dr. Voong is rated as an Experienced provider by MediFind in the treatment of Metastatic Brain Tumor. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Non-Small Cell Lung Cancer (NSCLC). Dr. Voong is board certified in American Board Of Radiology.

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as an Experienced provider by MediFind in the treatment of Metastatic Brain Tumor. She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Brahmer is board certified in American Board Of Internal Medicine.

Dr. Peter Kaplan is Professor of Neurology and serves as the Director of Epilepsy and EEG at Johns Hopkins Bayview Medical Center. He focuses on epilepsy, clinical neurophysiology and nonconvulsive status epilepticus. He has written extensively about these subjects as well as about eclampsia and neurologic disease in women. Dr. Peter Kaplan received his medical training from St. Bartholomews Medical School, University of London. He then obtained membership to the Royal College of Physicians in England. He completed his residency in neurology at Duke University Medical Center. He completed fellowships in epilepsy and clinical neurophysiology at the same institution. Dr. Kaplan currently sees patients at the Johns Hopkins Bayview Medical Center on Tuesdays and Wednesdays. Dr. Kaplan is rated as an Experienced provider by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Seizures, Generalized Tonic-Clonic Seizure, Status Epilepticus, Epilepsy, and Awake Craniotomy. Dr. Kaplan is board certified in American Board Of Psychiatry And Neurology.

Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs. Dr. Hann is rated as an Experienced provider by MediFind in the treatment of Metastatic Brain Tumor. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma. Dr. Hann is board certified in American Board Of Internal Medicine.

John Laterra is a Neurologist practicing medicine in Baltimore, Maryland. Dr. Laterra is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Stuart Grossman, M.D., is a professor of oncology at the Johns Hopkins Kimmel Cancer Center. He has served as Principal Investigator and Director of the Central Operations office of the National Cancer Institute-funded phase I/II brain tumor consortia (New Approaches to Brain Tumor Therapy CNS Consortium and the Adult Brain Tumor Consortium) for the past 22 years. He has led many phase I, II, and III institutional and cooperative group translational and clinical brain cancer research projects. Dr. Grossman's expertise is in brain cancers, translational and clinical research, and directing large, multicenter, multidisciplinary clinical trial groups and training programs. Dr. Grossman was an intern and resident at Strong Memorial Hospital in Rochester, NY, and a fellow at the Johns Hopkins University School of Medicine. He received his M.D. from the University of Rochester. Dr. Grossman is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri. Dr. Grossman is board certified in American Board Of Internal Medicine.

Dr. Daniel Laheru is a cancer specialist in Baltimore, caring for patients with pancreatic cancer, colorectal cancer and neuroendocrine cancers. Dr. Laheru serves as co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care at Johns Hopkins Medicine. Dr. Laheru received his undergraduate degree in chemistry from The University of Utah. He earned his M.D. at Baylor College of Medicine. He completed his residency at The University of Utah Hospital and Clinics and performed a fellowship in medical oncology at The Johns Hopkins University School of Medicine and The Johns Hopkins Oncology Center. Dr. Laheru joined the Johns Hopkins faculty in 2001. Dr. Laheru's research interests include pancreatic cancer and chemotherapy resistance in pancreatic cancer. With Elizabeth Jaffee, M.D., he developed a vaccine that supercharges the immune system and causes immune cells, which tend to be tolerant of cancer, to seek out and kill pancreatic cancer cells throughout the body. He has given numerous invited talks on pancreatic cancer and other cancers both nationally and internationally. He has authored over 200 papers focused on pancreatic cancer. Dr. Laheru serves as associate editor of Annals of Pancreatic Cancer. He has been recognized by the American Society of Clinical Oncology with the Young Investigator Award, by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as an Isaac and Catharine Hecht Scholar and has been elected to the Miller-Coulson Academy of Clinical Excellence. He is a member of the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Laheru is rated as an Advanced provider by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Laheru is board certified in American Board Of Internal Medicine.

Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is rated as an Advanced provider by MediFind in the treatment of Metastatic Brain Tumor. She is also highly rated in 27 other conditions, according to our data. Her clinical expertise encompasses Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy. Dr. Blakeley is board certified in American Board Of Psychiatry And Neurology.

Christopher Jackson is a neurosurgeon who specializes in brain tumors and cerebrovascular disorders, including glioma, meningioma, acoustic neuroma, trigeminal neuralgia, brain metastasis, arteriovenous malformation, and aneurysms. He is the director of the Acoustic Neuroma Center. Dr. Jackson earned his medical degree from the Johns Hopkins University School of Medicine, where he also completed his neurosurgical residency. During his residency, Dr. Jackson was honored with multiple distinctions, including the Frank L. Coulson Jr. Award for Clinical Excellence, the Irving J. Sherman Award for Resident Achievement, the Harvey Cushing Hunterian Research Award, and was elected to Alpha Omega Alpha. Dr. Jackson is an active researcher who has published over 35 peer-reviewed articles on brain tumor and cerebrovascular immunology. His laboratory focuses on how brain tumors evade the immune system and become resistant to immunotherapy. Additionally, Dr. Jackson’s laboratory explores the formation of cerebral aneurysms and inflammatory complications of cerebral aneurysm rupture. Dr. Jackson is rated as an Advanced provider by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Dysembryoplastic Neuroepithelial Tumors (DNET), Brain Stem Cancer, Posterior Fossa Tumor, Awake Craniotomy, and Gastrostomy. Dr. Jackson is board certified in American Board Of Neurological Surgery.